Our results demonstrate the antitumor activity of CBA-1205 in the liver cancer models, suggesting a potential therapeutic strategy by depletion of DLK1-positive cancer stem cells in HCC by ADCC activity of CBA-1205. This evidence concerns the gene DLK1 and cancer.